Evidence map›Paper›PMID 36911878›Full record

ArticleHeliyon2023

Application of the PHENotype SIMulator for rapid identification of potential candidates in effective COVID-19 drug repurposing.

Naomi I Maria, Rosaria Valentina Rapicavoli, Salvatore Alaimo, Evelyne Bischof, Alessia Stasuzzo, Jantine A C Broek, Alfredo Pulvirenti, Bud Mishra, Ashley J Duits, Alfredo Ferro and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 5 countries.

Naomi I MariaDepartment of Computer Science, Mathematics, Engineering and Cell Biology, Courant Institute, Tandon and School of Medicine, New York University, New York, USA.
Rosaria Valentina RapicavoliDepartment of Physics and Astronomy, University of Catania, Italy.
Salvatore AlaimoBioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy.
Evelyne BischofDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini, Naples, Italy.
Alessia StasuzzoDepartment of Chemical Sciences, University of Catania, Italy.
Jantine A C BroekDepartment of Computer Science, Mathematics, Engineering and Cell Biology, Courant Institute, Tandon and School of Medicine, New York University, New York, USA.
Alfredo PulvirentiBioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy.
Bud MishraDepartment of Computer Science, Mathematics, Engineering and Cell Biology, Courant Institute, Tandon and School of Medicine, New York University, New York, USA.
Ashley J DuitsRed Cross Blood Bank Foundation Curaçao, Willemstad, Curaçao.
Alfredo FerroBioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy.
RxCOVEA Framework
University of Catania · ITCold Spring Harbor Laboratory · USCourant Institute of Mathematical Sciences · USNorthwell Health · USShanghai University of Medicine and Health Sciences · CNUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current, rapidly diversifying pandemic has accelerated the need for efficient and effective identification of potential drug candidates for COVID-19. Knowledge on host-immune response to SARS-CoV-2 infection, however, remains limited with few drugs approved to date. Viable strategies and tools are rapidly arising to address this, especially with repurposing of existing drugs offering significant promise. Here we introduce a systems biology tool, the PHENotype SIMulator, which -by leveraging available transcriptomic and proteomic databases-allows modeling of SARS-CoV-2 infection in host cells

Indexed as

2DG, 2-Deoxy-GlucoseACE2, Angiotensin-converting enzyme 2Caco-2, Human colon epithelial carcinoma cell lineCalu-3, Epithelial cell lineCellular host-immune responseCellular SARS-CoV-2 signaturesCellular simulation modelsCOVID-19COVID-19, Coronavirus disease 2019DEGs, Differentially Expressed GenesDEPs, Differentially expressed proteinsDrug repurposingHCQ-CQ, (Hydroxy)chloroquineIFN, InterferonISGs, IFN-stimulated genesMITHrIL, Mirna enrIched paTHway Impact anaLysisMOI, Multiplicity of infectionMP, MethylprednisoloneNHBE, Normal human bronchial epithelial cellsPHENSIM, PHENotype SIMulatorSARS-CoV-2, Severe acute respiratory syndrome coronavirus 2Systems biologyTLR, Toll-like Receptor

Identifiers

PMID36911878
PMCPMC9986505
OpenAlexW4323317502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.